Особенности метаболизма витамина D у пациента с сахарным диабетом 1 типа, осложненным хронической болезнью почек и диабетической нейроостеоартропатией: клинический случай

Пациенты с множественными осложнениями сахарного диабета (СД) часто имеют значительные отклонения в параметрах кальций-фосфорного и костного метаболизма. Многофакторность патогенеза таких нарушений затрудняет ведение пациентов с длительным и осложненным течением СД. В данной статье представлено описание клинического случая пациента с длительным анамнезом СД 1 типа, трансплантацией почки в исходе терминальной почечной недостаточности и диабетической нейроостеоартропатией. Обсуждаются особенности метаболизма витамина D, важность своевременной диагностики фосфорно-кальциевых нарушений и особенности терапии пациента.

1. Jansen RB, Svendsen OL. A review of bone metabolism and developments in medical treatment of the diabetic Charcot foot. J Diabetes Complications. 2018;32(7):708-12. doi:10.1016/j.jdiacomp.2018.04.010.

2. Rosskopf AB, Loupatatzis C, Pfirrmann CWA, et al. The Charcot foot: a pictorial review. Insights Imaging. 2019;10(1):77. doi:10.1186/s13244-019-0768-9.

3. Yammine K, Hayek F, Assi C. Is there an association between vitamin D and diabetic foot disease? A meta-analysis. Wound Repair Regen. 2020;28(1):90-6. doi:10.1111/wrr.12762.

4. Greenhagen RM, Frykberg RG, Wukich DK. Serum vitamin D and diabetic foot complications. Diabet Foot Ankle. 2019;10(1):1579631. doi:10.1080/2000625X.2019.1579631.

5. Pilz S, Iodice S, Zittermann A, et al. Vitamin D status and mortality risk in CKD: a meta-analysis of prospective studies. Am J Kidney Dis. 2011;58(3):374-82. doi:10.1053/j.ajkd.2011.03.020.

6. Jayedi A, Soltani S, Shab-Bidar S. Vitamin D status and all-cause mortality in patients with chronic kidney disease: A systematic review and dose-response meta-analysis. J Clin Endocrinol Metab. 2017;102(7):2136-45. doi:10.1210/jc.2017-00105.

7. Chantelau EA, Grützner G. Is the Eichenholtz classification still valid for the diabetic Charcot foot? Swiss Med Wkly. 2014;144:w13948. doi:10.4414/smw.2014.13948.

8. Holmes C, Schmidt B, Munson M, Wrobel JS. Charcot stage 0: A review and consideratons for making the correct diagnosis early. Clin Diabetes Endocrinol. 2015;1:18. doi:10.1186/s40842-015-0018-0.

9. Bariteau JT, Tenenbaum S, Rabinovich A, Brodsky JW. Charcot arthropathy of the foot and ankle in patients with idiopathic neuropathy. Foot Ankle Int. 2014;35(10):996-1001. doi:10.1177/1071100714543649.

10. Patel DD, Vachhani U, Rajput A, et al. Analysis of the Prevalence and Severity of Dysregulated Bone Mineral Homeostasis in Nondialyzed Chronic Kidney Disease Patients. J Lab Physicians. 2022;14(2):144-50. doi:10.1055/s-0041-1732495.

11. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009;(113):S1-130. doi:10.1038/ki.2009.188.

12. KDOQI, National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis. 2006;47(5 Suppl 3):S11-145. doi:10.1053/j.ajkd.2006.03.010.

13. Tentori F, Blayney MJ, Albert JM, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2008;52(3):519-30. doi:10.1053/j.ajkd.2008.03.020.

14. Cailleaux PE, Ostertag A, Metzger M, et al. Longitudinal Bone Loss Occurs at the Radius in CKD. Kidney Int Rep. 2021;6(6):1525-36. doi:10.1016/j.ekir.2021.03.874.

15. Nickolas TL, McMahon DJ, Shane E. Relationship between moderate to severe kidney disease and hip fracture in the United States. J Am Soc Nephrol. 2006;17(11):3223-32. doi:10.1681/ASN.2005111194.

16. Ureña P, Bernard-Poenaru O, Ostertag A, et al. Bone mineral density, biochemical markers and skeletal fractures in haemodialysis patients. Nephrol Dial Transplant. 2003;18(11):2325-31. doi:10.1093/ndt/gfg403.

17. Moe SM, Nickolas TL. Fractures in Patients with CKD: Time for Action. Clin J Am Soc Nephrol. 2016;11(11):1929-31. doi:10.2215/CJN.09500916.

18. Iseri K, Carrero JJ, Evans M, et al. Incidence of Fractures Before and After Dialysis Initiation. J Bone Miner Res. 2020;35(12):2372-80. doi:10.1002/jbmr.4141.

19. Naylor KL, Garg AX, Zou G, et al. Comparison of fracture risk prediction among individuals with reduced and normal kidney function. Clin J Am Soc Nephrol. 2015;10(4):646-53. doi:10.2215/CJN.06040614.

20. Nitsch D, Mylne A, Roderick PJ, et al. Chronic kidney disease and hip fracture-related mortality in older people in the UK. Nephrol Dial Transplant. 2009;24(5):1539-44. doi:10.1093/ndt/gfn678.

21. Ureña Torres PA, Souberbielle JC, Solal MC. Bone Fragility in Chronic Kidney Disease Stage 3 to 5: The Use of Vitamin D Supplementation. Metabolites. 2022;12(3):266. doi:10.3390/metabo12030266.

22. Ketteler M, Block GA, Evenepoel P, et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what’s changed and why it matters. Kidney Int. 2017;92(1):26-36. doi:10.1016/j.kint.2017.04.006.

23. Zheng JS, Luan J, Sofianopoulou E, et al. The association between circulating 25-hydroxyvitamin D metabolites and type 2 diabetes in European populations: A meta-analysis and Mendelian randomisation analysis. PLoS Med. 2020;17(10):e1003394. doi:10.1371/journal.pmed.1003394.

24. Luo BA, Gao F, Qin LL. The Association between Vitamin D Deficiency and Diabetic Retinopathy in Type 2 Diabetes: A Meta-Analysis of Observational Studies. Nutrients. 2017;9(3):307. doi:10.3390/nu9030307.

25. Butler AE, Dargham SR, Latif A, et al. Association of vitamin D3 and its metabolites in patients with and without type 2 diabetes and their relationship to diabetes complications. Ther Adv Chronic Dis. 2020;11:2040622320924159. doi:10.1177/2040622320924159.

26. Yun HJ, Ryoo SR, Kim JE, et al. Trabecular bone score may indicate chronic kidney disease-mineral and bone disorder (CKD-MBD) phenotypes in hemodialysis patients: a prospective observational study. BMC Nephrol. 2020;21(1):299. doi:10.1186/s12882-020-01944-0.

27. Díaz López JB, Jorgetti V, Caorsi H, et al. Epidemiology of renal osteodystrophy in Iberoamerica. Nephrol Dial Transplant. 1998;13 Suppl 3:41-5. doi:10.1093/ndt/13.suppl_3.41.

28. Araújo SMHA, Ambrosoni P, Lobão RRS, et al. The renal osteodystrophy pattern in Brazil and Uruguay: an overview. Kidney Int Suppl. 2003;(85):S54-56. doi:10.1046/j.1523-1755.63.s85.13.x.

29. Oliveira RB de, Silva EN da, Charpinel DMF, et al. Secondary hyperparathyroidism status in Brazil: Brazilian census of parathyroidectomy. J Bras Nefrol. 2011;33(4):457-62.

30. Naves-Díaz M, Passlick-Deetjen J, Guinsburg A, et al. Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. The CORES Study. Nephrol Dial Transplant. 2011;26(6):1938-47. doi:10.1093/ndt/gfq304.

31. Fernández-Martín JL, Carrero JJ, Benedik M, et al. COSMOS: the dialysis scenario of CKD-MBD in Europe. Nephrol Dial Transplant. 2013;28(7):1922-35. doi:10.1093/ndt/gfs418.

32. Abrita RR, Pereira B dos S, Fernandes N da S, et al. Evaluation of prevalence, biochemical profile, and drugs associated with chronic kidney disease-mineral and bone disorder in 11 dialysis centers. J Bras Nefrol. 2018;40(1):26-34. doi:10.1590/2175-8239-JBN-3527.

33. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999;341(23):1725-30. doi:10.1056/NEJM199912023412303.

34. Torregrosa JV, Ferreira AC, Cucchiari D, Ferreira A. Bone Mineral Disease After Kidney Transplantation. Calcif Tissue Int. 2021;108(4):551-60. doi:10.1007/s00223-021-00837-0.

35. Torres A, Lorenzo V, Salido E. Calcium metabolism and skeletal problems after transplantation. J Am Soc Nephrol. 2002;13(2):551-8. doi:10.1681/ASN.V132551.

36. O’Brien CA, Jia D, Plotkin LI, et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology. 2004;145(4):1835-41. doi:10.1210/en.2003-0990.

37. Torres A, Torregrosa V, Marcen R, et al. Mineral metabolism disorders, vertebral frac tures and aortic calcifications in stable kidney transplant recipients: The role of gender (EMITRAL study). Nefrologia. 2016;36(3):255-67. doi:10.1016/j.nefro.2016.03.004.

38. Дедов И. И., Шестакова М. В., Майоров А. Ю., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией И. И. Дедова, М. В. Шестаковой, А. Ю. Майорова. 10-й выпуск. Сахарный диабет. 2021;24(1S):1-148. doi:10.14341/DM12802.

39. Лаевская М. Ю. Коррекция уровня витамина D у больных с терминальной стадией хронической болезни почек, находящихся на диализе. Клинический случай. РМЖ. Медицинское обозрение. 2019;1(I):44-8.

40. Шварц Г. Я. Дефицит витамина D и его фармакологическая коррекция. РМЖ. 2009;17(7):477-86.

41. Милованова Л. Ю., Добросмыслов И. А., Милованов Ю. С. Опыт применения активных метаболитов витамина D при нарушении фосфорно-кальциевого обмена у больных с додиализными стадиями хронической болезни почек. Терапевтический архив. 2014;86(6):52-6.

42. Hu X, Shang J, Yuan W, et al. Effects of paricalcitol on cardiovascular outcomes and renal function in patients with chronic kidney disease: A meta-analysis. Herz. 2018;43(6):518-28. doi:10.1007/s00059-017-4605-y.

43. Li XH, Feng L, Yang ZH, Liao YH. Effect of active vitamin D on cardiovascular outcomes in predialysis chronic kidney diseases: A systematic review and meta-analysis. Nephrology (Carlton). 2015;20(10):706-14. doi:10.1111/nep.12505.

44. Zhang T, Ju H, Chen H, Wen W. Comparison of Paricalcitol and Calcitriol in Dialysis Patients With Secondary Hyperparathyroidism: A Meta-Analysis of Randomized Controlled Studies. Ther Apher Dial. 2019;23(1):73-9. doi:10.1111/1744-9987.12760.

45. Elamin MB, Abu Elnour NO, Elamin KB, et al. Vitamin D and cardiovascular outcomes: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2011;96(7):1931-42. doi:10.1210/jc.2011-0398.

46. Alborzi P, Patel NA, Peterson C, et al. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension. 2008;52(2):249-55. doi:10.1161/HYPERTENSIONAHA.108.11315.

47. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(4 Suppl 3):S1-201.

48. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl (2011). 2017;7(1):1-59. doi:10.1016/j.kisu.2017.04.001.

49. Клинические рекомендации. Хроническая болезнь почек (ХБП). Нефрология. 2021;25(5):10-82.